{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:07:42Z","timestamp":1790957262214,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hypofractionation has potential benefits for cancer patients in low-income countries by reducing treatment duration and resource demands. However, few studies have examined the potential for higher toxicity due to the increased radiation dose per session, particularly in patients with existing health burdens like HIV. This study aimed to evaluate and compare the toxicity profiles of conventionally fractionated radiotherapy (CFRT) and hypofractionated radiotherapy (HFRT) in cervical cancer patients in a low-income setting, facilitating a better understanding of the associated risks and benefits to ensure safe and effective treatment options.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective cohort study was conducted at Inkosi Albert Luthuli Central Hospital (IALCH) in South Africa from March 2022 to March 2023. A total of 107 patients with confirmed cervical cancer were recruited and randomly assigned to either CFRT (n = 54; 50.50 Gy in 25 fractions) with weekly chemotherapy or HFRT (n = 53; 42.72 Gy in 16 fractions). Additionally, both groups received high-dose-rate (HDR) intracavitary brachytherapy, with doses of 18.00-, 21.00-, or 10.00-Gy boost. Clinical data and adverse events were recorded and analyzed, with statistical significance set at p &amp;lt; 0.05.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age at diagnosis was 36.4 (28.2\u201362.9) years, with 85.0% of patients under 40 years and 86.0% HIV-positive. Most patients in both groups presented with stage IIB and grade II disease. HFRT patients completed radiotherapy significantly faster (median, 35 days) than CFRT patients (median, 62 days) (p &amp;lt; 0.001). Both groups experienced similar rates of gastrointestinal (GI), genitourinary (GU), and skin toxicity, although significant differences were found in GI (p = 0.005) and GU (p = 0.01) side effects. Vaginal stenosis was more common in the CFRT group (51.9%) than in the HFRT group (43.4%). Both groups showed comparable clinical responses, recurrence-free survival, and absence of residual disease within 12 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HFRT (42.72 Gy in 16 fractions) offers comparable outcomes to CFRT (50.50 Gy in 25 fractions) with a shorter treatment duration, making it a feasible option in resource-limited settings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1552346","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:14:30Z","timestamp":1749010470000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A comparative analysis of hypofractionated versus conventional radiotherapy for cervical cancer in a resource-limited setting: a prospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Abba","family":"Mallum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen Bilinga","family":"Tendwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakiya","family":"Saidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twalib","family":"Ngoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Saiful","family":"Huq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Akudugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred","family":"Ngwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Incrocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariza","family":"Vorster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12939-023-01962-y","article-title":"Addressing cancer care inequities in sub-Saharan Africa: current challenges and proposed solutions","volume":"22","author":"Omotoso","year":"2023","journal-title":"Int J Equity Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e067715","DOI":"10.1136\/bmjopen-2022-067715","article-title":"Delays in seeking, reaching and access to quality cancer care in sub-Saharan Africa: a systematic review","volume":"13","author":"Lombe","year":"2023","journal-title":"BMJ Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00720-8","article-title":"Cancer in sub-Saharan Africa: a lancet oncology commission","volume":"23","author":"Ngwa","year":"2022","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.19.00261","article-title":"Can the adoption of hypofractionation guidelines expand global radiotherapy access? An analysis for breast and prostate radiotherapy","volume":"6","author":"Irabor","year":"2020","journal-title":"JCO Global Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4102\/sajo.v5i0.186","article-title":"A retrospective review of conventional versus hypo-fractionated pelvic radiotherapy for locally advanced cervical cancer, in limited-resource countries: The Uganda experience","volume":"5","author":"Kavuma","year":"2021","journal-title":"SA J Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.radonc.2012.12.001","article-title":"Accelerated fractionation with a concurrent boost for early stage breast cancer","volume":"106","author":"Freedman","year":"2013","journal-title":"Radiother Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2100360","DOI":"10.1200\/GO.21.00360","article-title":"A retrospective analysis of the impact of HIV infection on outcomes of locally advanced cervical cancers treated with either conventional or hypofractionated radiotherapy: The Uganda experience","volume":"8","author":"Kavuma","year":"2022","journal-title":"JCO Global Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12961-023-01094-3","article-title":"Drivers of cervical cancer prevention and management in sub-Saharan Africa: a qualitative synthesis of mixed studies","volume":"22","author":"Atnafu","year":"2024","journal-title":"Health Res Policy Syst"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.33696\/cancerimmunol.3.043","article-title":"Cervical Cancer prevalence in sub-Saharan Africa and HPV vaccination policy: a public health grand challenge","volume":"3","author":"Asempah","year":"2021","journal-title":"J Cancer Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.618641","article-title":"Hypofractionated radiotherapy in African cancer centers","volume":"10","author":"Swanson","year":"2021","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1879646","article-title":"Optimal treatment in locally advanced cervical cancer","volume":"21","author":"Gennigens","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.6004\/jnccn.2022.0008","article-title":"National comprehensive cancer network nccn clinical practice guidelines in oncology","volume":"2","author":"Ajani","year":"2019","journal-title":"Gastric Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"200238","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: Current challenges and future perspectives","volume":"13","author":"Burmeister","year":"2022","journal-title":"Tumour Virus Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e8","article-title":"Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study","volume":"31","author":"Li","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003952","article-title":"Radical trachelectomy for the treatment of early-stage cervical cancer: a systematic review","volume":"136","author":"Smith","year":"2020","journal-title":"Obstet Gynecol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S351744","article-title":"Technological advancements in external beam radiation therapy (EBRT): An indispensable tool for cancer treatment","volume":"14","author":"Koka","year":"2022","journal-title":"Cancer Manage Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5114\/jcb.2017.72607","article-title":"Current status of brachytherapy in cancer treatment\u2013short overview","volume":"9","author":"Skowronek","year":"2017","journal-title":"J Contemp Brachyther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090587","article-title":"The current trend of radiation therapy for patients with localized prostate cancer","volume":"30","author":"Numakura","year":"2023","journal-title":"Curr Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4102\/sajo.v1i0.28","article-title":"Hypofractionation and prostate cancer: A good option for Africa","volume":"1","author":"Incrocci","year":"2017","journal-title":"South African Journal of Oncology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.04.002","article-title":"Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer","volume":"58","author":"Yang","year":"2021","journal-title":"Breast"},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.breast.2019.08.001","article-title":"Meta-analysis of long-term efficacy and safety of hypofractionated radiotherapy in the treatment of early breast cancer","volume":"48","author":"Andrade","year":"2019","journal-title":"Breast"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jmiro.2015.59.issue-2","article-title":"Hypofractionated radiation treatment following mastectomy in early breast cancer: The C hristchurch experience","volume":"59","author":"Ko","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0565","article-title":"Postoperative hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy in cervical cancer: the POHIM-CCRT nonrandomized controlled trial","volume":"10","author":"Cho","year":"2024","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/pathogens13030243","article-title":"Unveiling the dual threat: how microbial infections and healthcare deficiencies fuel cervical and prostate cancer deaths in africa","volume":"13","author":"Abdul-Nasir","year":"2024","journal-title":"Pathogens"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000441","article-title":"HIV status and acute hematologic toxicity among patients with cervix cancer undergoing radical chemoradiation","volume":"25","author":"Simonds","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100552","article-title":"Dose\u2013volume constraints fOr oRganS At risk In Radiotherapy (CORSAIR): an \u201cAll-in-One\u201d multicenter\u2013multidisciplinary practical summary","volume":"29","author":"Bisello","year":"2022","journal-title":"Curr Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.040","article-title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","volume":"76","author":"Bentzen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B34","first-page":"785","article-title":"Common terminology criteria for adverse events","volume":"784","author":"Shah","year":"2022","journal-title":"Natl Cancer Inst: USA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100682","DOI":"10.1016\/j.ctarc.2023.100682","article-title":"Cervical cancer screening in HIV-endemic countries: an urgent call for guideline change","volume":"34","author":"Grover","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"B36","volume-title":"Key Statistics for Cervical Cancer","year":"2024"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e31826e4609","article-title":"Cervical carcinoma rates among young females in the United States","volume":"120","author":"Benard","year":"2012","journal-title":"Obstet Gynecol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e0000941","DOI":"10.1371\/journal.pgph.0000941","article-title":"Early-onset of sexual activity as a potential risk of cervical cancer in Africa: A review of literature","volume":"3","author":"Mekonnen","year":"2023","journal-title":"PloS Global Public Health"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Global Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11754","article-title":"Cervical cancer in low and middle\u2212income countries","volume":"20","author":"Hull","year":"2020","journal-title":"Oncol Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4172\/1948-5956.1000473","article-title":"Socio-demographic factors associated with advanced stage of cervical cancer at diagnosis in Kenyatta national hospital, Kenya: A cross sectional study","volume":"9","author":"Frida","year":"2017","journal-title":"J Cancer Sci Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e007690","DOI":"10.1136\/bmjopen-2015-007690","article-title":"Social, demographic and healthcare factors associated with stage at diagnosis of cervical cancer: cross-sectional study in a tertiary hospital in Northern Uganda","volume":"6","author":"Mwaka","year":"2016","journal-title":"BMJ Open"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-018-6065-6","article-title":"Factors associated with late presentation of cervical cancer cases at a district hospital: a retrospective study","volume":"18","author":"Dunyo","year":"2018","journal-title":"BMC Public Health"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.1984","article-title":"An analysis of delays in treatment time for prostate cancer patients in sub-saharan Africa","volume":"117","author":"Patel","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1747","article-title":"Treatment delays for cancer patients in Sub-Saharan Africa: South Africa as a microcosm","volume":"18","author":"Mallum","year":"2025","journal-title":"Journal of  Ecancermedicalscience"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2022.10.002","article-title":"Role of brachytherapy in post-operative cervical cancer patients with risk factors other than positive stump","volume":"22","author":"Yu","year":"2023","journal-title":"Brachytherapy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2577","article-title":"Magnetic resonance-guided external beam radiation and brachytherapy for a patient with intact cervical cancer","volume":"10","author":"Asher","year":"2018","journal-title":"Cureus"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/cancers16020362","article-title":"Hypofractionated radiotherapy in gynecologic Malignancies\u2014A peek into the upcoming evidence","volume":"16","author":"Amjad","year":"2024","journal-title":"Cancers"},{"key":"B51","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.ijrobp.2022.07.500","article-title":"A pilot study of moderately hypo-fractionated whole pelvic radiotherapy with concurrent chemotherapy and image-guided high dose rate brachytherapy for locally advanced cervical carcinoma","volume":"114","author":"Gandhi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2022.2048070","article-title":"Phase 1\/2 trial evaluating the effectiveness and safety of dose-adapted Hypofractionated pelvic radiotherapy for Advanced Cervical cancers INeligible for ChemoTherapy (HYACINCT)","volume":"61","author":"Bacorro","year":"2022","journal-title":"Acta Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.ijrobp.2023.06.313","article-title":"HYPOCx-iRex (TCTR20210812003) A phase II RCT: 44 gy\/20F VS 45 gy\/25F CCRT in cervical cancer: six-month post-RT update","volume":"117","author":"Prasartseree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.02.015","article-title":"Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions","volume":"97","author":"Souhami","year":"2005","journal-title":"Gynecol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2022.11.005","article-title":"Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy","volume":"22","author":"Scott","year":"2023","journal-title":"Brachytherapy"},{"key":"B56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ctrv.2016.07.003","article-title":"The prospect of precision therapy for renal cell carcinoma","volume":"49","author":"Ciccarese","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.semradonc.2012.11.003","article-title":"Physics controversies in proton therapy","author":"Engelsman","year":"2013","journal-title":"Semin Radiat Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13014-022-01995-7","article-title":"Hypofractionated radiation leads to more rapid bleeding cessation in women with vaginal bleeding secondary to gynecologic Malignancy","volume":"17","author":"Moradi","year":"2022","journal-title":"Radiat Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.1660","article-title":"Radiation-induced vaginal stenosis in patients with locally advanced cervical cancer","volume":"111","author":"Williamson","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2016.5.issue-9","article-title":"Impact of treatment time-related factors on prognoses and radiation proctitis after definitive chemoradiotherapy for cervical cancer","volume":"5","author":"Huang","year":"2016","journal-title":"Cancer Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2012.05.002","article-title":"Impact of age and comorbidity on treatment and outcomes in elderly cancer patients","author":"Chen","year":"2012","journal-title":"Semin Radiat Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21689","article-title":"Radiation therapy-associated toxicity: Etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA: A Cancer J Clin"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1552346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:14:31Z","timestamp":1749010471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1552346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":62,"alternative-id":["10.3389\/fonc.2025.1552346"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1552346","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1552346"}}